Kyverna Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KYTX Nasdaq 2836 kyvernatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kyverna Therapeutics, Inc.

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel - Jul 27th, 2026 6:00 am
Kyverna Therapeutics Sinks 13%: Here’s Why - Jul 10th, 2026 1:59 pm
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond - Jul 9th, 2026 7:22 am
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition - Jun 22nd, 2026 6:00 am
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - Jun 8th, 2026 12:54 pm
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis - Jun 3rd, 2026 6:00 am
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - May 18th, 2026 6:00 am
KYV-101 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - May 15th, 2026 3:04 am
Kyverna Therapeutics to Present at Upcoming Investor Conferences - May 14th, 2026 6:00 am
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B - May 13th, 2026 4:27 am
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - May 12th, 2026 2:02 pm
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer - May 4th, 2026 6:00 am
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA - Apr 25th, 2026 6:31 am
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting - Apr 21st, 2026 4:45 pm
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks - Apr 20th, 2026 6:00 am
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 - Apr 9th, 2026 6:00 am
The Oncology Institute Names Minh Merchant Chief Legal Officer - Apr 6th, 2026 7:00 am
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 26th, 2026 2:02 pm
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - Mar 5th, 2026 2:21 pm
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Mar 3rd, 2026 6:00 am